BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 24504503)

  • 21. Exploring spatial overlap of high-uptake regions derived from dual tracer positron emission tomography-computer tomography imaging using 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine in nonsmall cell lung cancer patients: a prospective pilot study.
    Liu J; Li C; Hu M; Lu J; Shi X; Xing L; Sun X; Fu Z; Yu J; Meng X
    Medicine (Baltimore); 2015 May; 94(17):e678. PubMed ID: 25929896
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PET with [18F]fluorothymidine for imaging of primary breast cancer: a pilot study.
    Smyczek-Gargya B; Fersis N; Dittmann H; Vogel U; Reischl G; Machulla HJ; Wallwiener D; Bares R; Dohmen BM
    Eur J Nucl Med Mol Imaging; 2004 May; 31(5):720-4. PubMed ID: 14991243
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 18F-FLT PET/CT for early response monitoring and dose escalation in oropharyngeal tumors.
    Troost EG; Bussink J; Hoffmann AL; Boerman OC; Oyen WJ; Kaanders JH
    J Nucl Med; 2010 Jun; 51(6):866-74. PubMed ID: 20484426
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Detection of gastric cancer using 18F-FLT PET: comparison with 18F-FDG PET.
    Kameyama R; Yamamoto Y; Izuishi K; Takebayashi R; Hagiike M; Murota M; Kaji M; Haba R; Nishiyama Y
    Eur J Nucl Med Mol Imaging; 2009 Mar; 36(3):382-8. PubMed ID: 18985344
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Parametric Method Performance for Dynamic 3'-Deoxy-3'-
    Kramer GM; Frings V; Heijtel D; Smit EF; Hoekstra OS; Boellaard R;
    J Nucl Med; 2017 Jun; 58(6):920-925. PubMed ID: 28572289
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Kinetic analysis of 3'-deoxy-3'-(18)F-fluorothymidine ((18)F-FLT) in head and neck cancer patients before and early after initiation of chemoradiation therapy.
    Menda Y; Boles Ponto LL; Dornfeld KJ; Tewson TJ; Watkins GL; Schultz MK; Sunderland JJ; Graham MM; Buatti JM
    J Nucl Med; 2009 Jul; 50(7):1028-35. PubMed ID: 19525472
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Imaging of proliferation in hepatocellular carcinoma with the in vivo marker 18F-fluorothymidine.
    Eckel F; Herrmann K; Schmidt S; Hillerer C; Wieder HA; Krause BJ; Schuster T; Langer R; Wester HJ; Schmid RM; Schwaiger M; Buck AK
    J Nucl Med; 2009 Sep; 50(9):1441-7. PubMed ID: 19690030
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer.
    Liao S; Penney BC; Wroblewski K; Zhang H; Simon CA; Kampalath R; Shih MC; Shimada N; Chen S; Salgia R; Appelbaum DE; Suzuki K; Chen CT; Pu Y
    Eur J Nucl Med Mol Imaging; 2012 Jan; 39(1):27-38. PubMed ID: 21946983
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 3'-deoxy-3'-18F-fluorothymidine PET/CT to guide therapy with epidermal growth factor receptor antagonists and Bcl-xL inhibitors in non-small cell lung cancer.
    Zannetti A; Iommelli F; Speranza A; Salvatore M; Del Vecchio S
    J Nucl Med; 2012 Mar; 53(3):443-50. PubMed ID: 22331221
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Repeatability of metabolically active volume measurements with 18F-FDG and 18F-FLT PET in non-small cell lung cancer.
    Frings V; de Langen AJ; Smit EF; van Velden FH; Hoekstra OS; van Tinteren H; Boellaard R
    J Nucl Med; 2010 Dec; 51(12):1870-7. PubMed ID: 21078791
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG.
    Chen W; Cloughesy T; Kamdar N; Satyamurthy N; Bergsneider M; Liau L; Mischel P; Czernin J; Phelps ME; Silverman DH
    J Nucl Med; 2005 Jun; 46(6):945-52. PubMed ID: 15937304
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of 18F-FLT PET and 18F-FDG PET in esophageal cancer.
    van Westreenen HL; Cobben DC; Jager PL; van Dullemen HM; Wesseling J; Elsinga PH; Plukker JT
    J Nucl Med; 2005 Mar; 46(3):400-4. PubMed ID: 15750150
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Repeatability of quantitative
    Kramer GM; Liu Y; de Langen AJ; Jansma EP; Trigonis I; Asselin MC; Jackson A; Kenny L; Aboagye EO; Hoekstra OS; Boellaard R;
    Eur J Nucl Med Mol Imaging; 2018 Jun; 45(6):951-961. PubMed ID: 29362858
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of Platinum-Based Chemoradiotherapy on Cellular Proliferation in Bone Marrow and Spleen, Estimated by (18)F-FLT PET/CT in Patients with Locally Advanced Non-Small Cell Lung Cancer.
    Leimgruber A; Möller A; Everitt SJ; Chabrot M; Ball DL; Solomon B; MacManus M; Hicks RJ
    J Nucl Med; 2014 Jul; 55(7):1075-80. PubMed ID: 24868108
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of 3'-deoxy-3'-[¹⁸F]fluorothymidine positron emission tomography (FLT PET) and FDG PET/CT for the detection and characterization of pancreatic tumours.
    Herrmann K; Erkan M; Dobritz M; Schuster T; Siveke JT; Beer AJ; Wester HJ; Schmid RM; Friess H; Schwaiger M; Kleeff J; Buck AK
    Eur J Nucl Med Mol Imaging; 2012 May; 39(5):846-51. PubMed ID: 22278320
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [18F]FLT-PET and [18F]FDG-PET in the evaluation of radiotherapy for laryngeal cancer.
    Been LB; Hoekstra HJ; Suurmeijer AJ; Jager PL; van der Laan BF; Elsinga PH
    Oral Oncol; 2009 Dec; 45(12):e211-5. PubMed ID: 19692292
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Early determination of prognosis by interim 3'-deoxy-3'-18F-fluorothymidine PET in patients with non-Hodgkin lymphoma.
    Lee H; Kim SK; Kim YI; Kim TS; Kang SH; Park WS; Yun T; Eom HS
    J Nucl Med; 2014 Feb; 55(2):216-22. PubMed ID: 24365650
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of residual metabolic-active areas within individual NSCLC tumours using a pre-radiotherapy (18)Fluorodeoxyglucose-PET-CT scan.
    Aerts HJ; van Baardwijk AA; Petit SF; Offermann C; Loon Jv; Houben R; Dingemans AM; Wanders R; Boersma L; Borger J; Bootsma G; Geraedts W; Pitz C; Simons J; Wouters BG; Oellers M; Lambin P; Bosmans G; Dekker AL; De Ruysscher D
    Radiother Oncol; 2009 Jun; 91(3):386-92. PubMed ID: 19329207
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The contribution of integrated PET/CT to the evolving definition of treatment volumes in radiation treatment planning in lung cancer.
    Ashamalla H; Rafla S; Parikh K; Mokhtar B; Goswami G; Kambam S; Abdel-Dayem H; Guirguis A; Ross P; Evola A
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(4):1016-23. PubMed ID: 15979817
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Early Prediction of Radiotherapeutic Efficacy in a Mouse Model of Non-Small Cell Lung Carcinoma Using
    Otani T; Ikushima H; Bando Y; Yamashita M; Kuwahara K; Otsuka H; Kondo K; Miyoshi H
    J Med Invest; 2023; 70(3.4):361-368. PubMed ID: 37940520
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.